Compare ALRS & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALRS | ZVRA |
|---|---|---|
| Founded | 1879 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 831.8M | 689.4M |
| IPO Year | 2019 | 2015 |
| Metric | ALRS | ZVRA |
|---|---|---|
| Price | $31.71 | $10.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $35.40 | $25.00 |
| AVG Volume (30 Days) | 121.5K | ★ 746.1K |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.79% | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | ★ 1.70 | 0.74 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | $5.94 | $42.97 |
| Revenue Next Year | $2.67 | $16.27 |
| P/E Ratio | $18.65 | ★ $15.19 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $20.31 | $8.01 |
| 52 Week High | $34.40 | $15.04 |
| Indicator | ALRS | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 32.82 | 35.04 |
| Support Level | $30.13 | $10.18 |
| Resistance Level | $31.86 | $11.07 |
| Average True Range (ATR) | 0.67 | 0.38 |
| MACD | -0.15 | -0.11 |
| Stochastic Oscillator | 0.00 | 0.32 |
Alerus Financial Corp is a financial holding company registered in the United States. The company operates in four segments: Banking, Retirement & Benefit Services, Wealth Management, and others. The company provides various banking services such as checking, debit cards, savings, current deposits, loans and advances, online banking, mobile banking, private banking, payment solutions, and other business products. Additionally, the company provides mortgage loans, retirement planning solutions, individual retirement accounts, retirement plan advisory services and wealth management services, including retirement plans, and fiduciary services. The company's revenue mainly consists of interest income, commission, management fees, and other income.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.